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Background and objective: The neutrophil-to-lymphocyte ratio has demonstrated to be a prog-
nostic  inﬂammatory marker in cardiovascular disease. The objective of this study is to
evaluate the association between neutrophil–lymphocyte ratio and pathologic urinary albu-
min/creatinine ratio as an early marker of cardiovascular risk and systemic endothelial
dysfunction, associated with microvascular disease, in asymptomatic subjects.
Materials and methods: A unicenter cross-sectional study was conducted, including 1816
asymptomatic subjects. Patients with previous cardiovascular disease, those who were
treated with ACE inhibitors and/or angiotensin II receptor blockers and patients with albu-
min/creatinine ratio over 300 mg/g were excluded. The outcome of the study was  the
presence of a pathologic urinary albumin/creatinine ratio.
Results: The neutrophil–lymphocyte ratio was signiﬁcantly associated with altered urinary
albumin/creatinine ratio in the univariate analysis and after adjustment for other known
endothelial and cardiovascular risk factors (age, hypertension, dyslipidaemia, diabetes or
altered glomerular ﬁltration rate). Based on the sensitivity and speciﬁcity of different
neutrophil–lymphocyte ratio thresholds, 3 risk groups were created for altered urinary albu-
min/creatinine ratio: low risk in those with neutrophil–lymphocyte ratio <1.5, intermediate
risk  in patients between 1.5 and 3, and high risk in those with neutrophil- to-lymphocyte
ratio >3. These groups were found to have a statistically signiﬁcant and independent prog-
nostic power for altered urinary albumin/creatinine ratio in asymptomatic patients.
Conclusions: The neutrophil–lymphocyte ratio appears to be a cost-efﬁcient, non-invasive
and independent potential marker of systemic endothelial dysfunction in asymptomatic
subjects.©  2015 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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El  índice  neutróﬁlo/linfocito  como  marcador  de  disfunción  sistémica
endotelial  en  sujetos  asintomáticos
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Fundamento y objetivo: El índice neutróﬁlo/linfocito es un marcador inﬂamatorio devalor
pronóstico en enfermedades cardiovasculares. El objetivo del presente trabajo esvalorar
la  asociación entre el índice neutróﬁlo/linfocito y la alteración del cociente albú-
mina/creatinina urinario como marcador precoz de disfunción endotelial sistémica
asociadaa enfermedad microvascular y riesgo cardiovascular, en sujetos asintomáticos.
Materiales y métodos: Se realizó un estudio transversal en 1.816 sujetos asintomáticos.
Seexcluyó del a estudio aquellos pacientes que presentaron antecedentes de enfermedad
car-diovascular, los que recibían tratamiento con fármacos antiproteinúricos (inhibidores de
laenzima conversora de angiotensina y antagonistas de los receptores de la angiotensina
II)  yaquellos que presentaron un cociente albúmina/creatinina superior a 300 mg/dL. La
variabledesenlace del estudio fue la alteración del cociente albúmina/creatinina urinario.
Resultados: El índice neutróﬁlo/linfocito resultó signiﬁcativamente asociado a la alteración-
del  cociente albúmina/creatinina urinario, tanto en el estudio univariante como en el
mul-tivariante, independientemente de otros cofactores como la edad, la hipertensión
arterial,la diabetes, la dislipidemia o el ﬁltrado glomerular patológico. El análisis de la
sensibilidad yla especiﬁcidad de distintos niveles del índice neutróﬁlo/linfocito permitió
generar 3 gruposde riesgo de alteración del cociente albúmina/creatina urinario: riesgo bajo
con un cocienteneutróﬁlo/linfocito < 1,5, riesgo intermedio con cociente neutróﬁlo/linfocito
entre 1,5 y 3 yriesgo alto con un cociente neutróﬁlo/linfocito > 3. La proporción relativa de
alteración delcociente albúmina/creatinina urinario, en los 3 grupos de riesgo, aumentaba
en  razón delvalor del índice neutróﬁlo/linfocito de forma independiente al resto de cofac-
tores.
Conclusiones: El índice neutróﬁlo/linfocito surge como un potencial marcador de disfun-ción
endotelial sistémica económico, rápido, no invasivo e independiente de otros factorescono-
cidos, en sujetos asintomáticos.
© 2015 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
Each year, cardiovascular diseases (CVDs) cause around
4 million deaths in Europe and 1.9 million deaths in the Euro-
pean Union, accounting for 47% of all deaths in Europe and
40% of all deaths in the European Union. CVDs are the most
common cause of death in women in all European countries
and the most common cause of death in men  in at least 6 of
them. CVDs cost D 196,000 million each year in Europe (54% in
healthcare spending, 24% in lost productivity and 22% in the
care of patients with CVD).1
The high prevalence of cardiovascular risk factors,
especially smoking, obesity and diabetes, promotes the devel-
opment of CVDs, and therefore detection and management of
cardiovascular risk factors is very important. The World Health
Organisation believes that 75% of deaths due to CVDs could
be prevented with suitable changes in lifestyle and modiﬁca-
tion of risk factors.2 Therefore, early detection of patients with
cardiovascular risk is an objective of major importance. To this
end, an abnormal urinary albumin/creatinine ratio (UACR) has
been shown to be an early marker of cardiovascular morbidity
and mortality.3by-nc-nd/4.0/).
Noteworthy among the mechanisms involved between an
abnormal UACR and CVDs is endothelial dysfunction, at both
the microvascular level (decrease in nitric oxide, increase
in von Willebrand factor, vascular endothelial growth factor,
asymmetric dimethylarginine [ADMA]) and the macrovascular
level (vessel dilatation).4 This damage is due in part to inﬂam-
mation of the endothelium of the microvasculature, which
promotes the accumulation of lipids and the development of
atherosclerosis.5
Inﬂammation plays a central role in the physiopathology
of diseases that are considered to be non-inﬂammatory, such
as cancer and atherosclerosis.6–11 The determination of cir-
culating peripheral blood leukocytes is a simple, inexpensive
and widely available method that helps to assess inﬂam-
mation. Among the various leucocyte parameters, the ratio
absolute neutrophil count to the absolute lymphocyte count
(neutrophil–lymphocyte ratio [NLR]) is signiﬁcantly associ-
ated to elevation pro-inﬂammatory cytokine concentration
and development of CVD and progression.12–14 This param-
eter has been shown to be an inﬂammatory marker with a
high predictive power of death, acute myocardial infarction
and severity of coronary heart disease.14–16 In addition, various
studies have investigated the link between NLR  and diabetes
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abnormal UACR was 8%, which was similar to that of the
general population (p > 0.5). No statistically signiﬁcant differ-
ences were found in CRP levels in patients with an abnormal
Table 1 – Clinical characteristics of the population
(n = 1816).
Characteristic
Family history of CVD (%) 174 (9.6)
Age (years) 52.89 ± 10.94
Age quartiles (range of years)
Quartile 1 (18–45) 38.91 ± 0.24
Quartile 2 (46–53) 49.74 ± 0.1
Quartile 3 (54–60) 56.95 ± 0.09
Quartile 4 (61–87) 66.98 ± 0.24
Males (%) 1386 (76.3)
BMI (kg/m2) 27.94 ± 4.22
Smoking (%) 478 (26.3)
Systolic blood pressure (mmHg) 124.01 ± 19.29
Diastolic blood pressure (mmHg) 79.59 ± 9.51
Glucose (mg/dl) 100.44 ± 26.13
HOMA-IR (U·mmol/l2) 2.63 ± 2.36
Insulin (U/ml) 10.45 ± 7.66
HDL (mg/dl) 53.34 ± 15.40
LDL (mg/dl) 142.77  ± 38.08
Total cholesterol (mg/dl) 219 ± 41.09
Triglycerides (mg/dl) 117.69 ± 80.63
Neutrophils (109/l) 3.66 ± 1.31
Lymphocytes (109/l) 1.93 ± 0.56
NLR 2.00 ± 0.83
C-reactive protein (mg/dl)a 0.49 ± 0.04
Creatinine (mg/dl) 0.95 ± 0.19
eGFR (ml/min/1.73 m2) 76 ± 4.2
Albumin/creatinine (mg/g) 11.46 ± 22.79
Hypertension (%) 612 (33.7)
Diabetes mellitus (%) 249 (13.7)
Dyslipidaemia (%) 934 (51.4)
Abnormal UACR (%) 137 (7.5)
UACR, urinary albumin/creatinine ratio; CVD, cardiovascular dis-
ease; eGFR, estimated glomerular ﬁltration rate; HDL, high-densityn e f r o l o g i a. 2 0 
ellitus, insulin resistance as assessed by the Homoeostasis
odel Assessment of Insulin Resistance (HOMA-IR), hyper-
ension, obesity, hyperlipidaemia, lifestyle and endothelial
ysfunction.17–19
To date, studies about the association between NLR and
VDs have been performed in patients with symptomatic
VD. The objective of this study was to evaluate whether this
ssociation is observed in asymptomatic subjects without a
rior history of CVD, using an abnormal UACR as an early
arker of systemic endothelial damage and cardiovascular
isk.
aterials  and  methods
 cross-sectional study was conducted with patients from sev-
ral regions of Spain who  visited the Clínica Universidad de
avarra for routine medical check-up and an estimation of
ardiovascular risk. A total of 2246 clinically asymptomatic
atients were evaluated since May 1999–January 2011. Each
atient underwent a complete medical history that included
he collection of family histories of CVD, as well as gen-
ral laboratory testing with a complete blood count, blood
hemistry, cholesterol fractions and the determination of
lbumin and creatinine in urine from ﬁrst urination. Patients
ere excluded if they had a personal history of cardiovascu-
ar events (acute myocardial infarction, stroke or peripheral
rtery disease), were on antiproteinuric drugs (angiotensin
onverting enzyme inhibitors and angiotensin II receptor
ntagonists) or had a UACR >300 mg/g. The 1816 remaining
ubjects were enrolled in the ﬁnal cohort. The study was
esigned in accordance with the Declaration of Helsinki and
he protocol was approved by the Clínica Universidad de
avarra Ethics Committee.
Cardiovascular risk factors were deﬁned according to the
uidelines of the modiﬁed Adult Treatment Panel (ATP)-III.20
aboratory determinations were made using standard labo-
atory techniques. To calculate the NLR, the ratio absolute
eutrophil count to absolute lymphocyte count was obtained
rom the complete blood count. To evaluate insulin resistance,
he HOMA-IR was used as both a continuous variable and
s values above or below the cut-off point of 2.19 The Mod-
ﬁcation of Diet in Renal Disease formula was used for the
stimated glomerular ﬁltration rate (eGFR)„ and it was con-
idered to be pathological below 60 ml/min/1.73 m2. A urinary
lbumin/creatinine ratio between 30 and 300 mg/g was used as
 marker of endothelial dysfunction and cardiovascular risk.21
The results were expressed as the value of the arith-
etic mean ± standard deviation for continuous quantitative
ariables. Qualitative variables were presented in the form
f proportions. Univariate statistical analysis was performed
sing hypothesis-corroborating tests: the chi-squared test for
ualitative variables, Student’s t test for comparisons of quan-
itative variables with homogeneity of variances in Levene’s
est and the Mann–Whitney U test in the rest. Multivariate
nalysis was performed using logistic regression models. A
ensitivity analysis was performed to seek the values with the
reatest discriminatory capacity. In the results of this analy-
is, the parameters with the highest sensitivity and speciﬁcity(4):397–403 399
were considered to be clinically useful.22 Statistical calcula-
tions were performed using the SPSS version 20.0 program.
Results
Table 1 shows the clinical characteristics of the study popula-
tion. Mean NLR was 2 ± 0.83. Abnormal UACR was observed in
7.5% of patients.
As shown in Table 2, abnormal UACR was signiﬁcantly asso-
ciated with age, obesity, hypertension, diabetes, insulin resis-
tance (HOMA-IR > 2), dyslipidaemia and <60 ml/min/1.73 m2 of
eGFR. The same table shows a signiﬁcant increase in NLR in
patients with an abnormal UACR. C-reactive protein (CRP) was
used to evaluate an abnormal UACR’s capacity for predicting
other markers of inﬂammation. This analysis was performed
in a subgroup of the patients in which this determination
was available (n = 439). In this subgroup, the prevalence of anlipoprotein; HOMA-IR, Homeostatic Model Assessment of Insulin
Resistance; BMI, body mass index; NLR, neutrophil–lymphocyte
ratio; LDL, low density lipoprotein.
a The results for a subgroup of 439 patients are included.
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Table 2 – Univariate analysis of the association of different cardiovascular risk factors with an abnormal UACR.
Normal UACR (n = 1679) Abnormal UACR (n = 137) p
Family history of CVD (%) 158 (9.4) 18 (13.1) NS
Age (years) 52.46 ± 10.82 58.12 ± 11.15 <0.01
Males (%) 1275  (75.94) 111 (81.02) NS
Obesity (%) 437 (26.03) 55 (40.15) <0.01
Smoking (%) 435 (25.95) 43 (31.42) NS
Hypertension (%) 520 (31.06) 92 (67.21) <0.01
Type 2 diabetes mellitus (%) 197 (11.72) 52 (38.03) <0.01
HOMA-IR > 2 (%) 689 (50.6) 79 (73.8) <0.01
Dyslipidaemia (%) 842 (52.07) 92 (72.46) <0.01
Pathological eGFR (%) 72 (4.3) 18 (13.1) <0.01
NLR 1.97 ± 0.80 2.30 ± 1.16 <0.01
C-reactive protein (mg/dl)a 0.56 ± 0.50 0.49 ± 0.90 NS
UACR, urinary albumin/creatinine ratio; CVD, cardiovascular disease; eGFR, estimated glomerular ﬁltration rate; HOMA-IR, Homeostatic Model
.Assessment of Insulin Resistance; NLR, neutrophil–lymphocyte ratio
a The results for a subgroup of 439 patients are included.
UACR as compared with a UACR within normal limits (p < 0.45).
Nevertheless, in this subgroup of 439 patients, NLR remained
signiﬁcantly associated with an abnormal UACR (p < 0.05).
After the univariate analysis, a logistic regression model
was prepared including all the previously signiﬁcant variables.
As shown in Table 3, all the vascular risk factors except obe-
sity remained signiﬁcantly and independently associated with
an abnormal UACR. The NLR value remained an indepen-
dent marker of an abnormal UACR (OR: 1.45. p < 0.01). In an
alternative model, the HOMA-IR was changed by diabetes to
avoid collinearity. The HOMA-IR was signiﬁcant in identify-
ing an abnormal UACR (OR: 1.11; p < 0.01), and the predictive
power of NLR’s persisted. Table complementary 1 presents
this model. In the subgroup of 439 patients whose CRP lev-
els were available, 2 multivariate models were tested with
the same adjustment variables. The ﬁrst model used the NLR
to predict inﬂammation; it was signiﬁcantly associated with
an abnormal UACR (OR: 1.6; p < 0.01; Table complementary 2).
By contrast, the second model that used CRP as a marker
of inﬂammation, it was not signiﬁcantly associated with an
abnormal UACR (OR: 0.94; p > 0.05; Table complementary 3).
Subsequently, the relationship between the NLR and the
different cardiovascular risk factors was studied. In our study,
hypertension, diabetes, smoking and obesity were not asso-
ciated with the NLR. Moreover, the anti-inﬂammatory effect
of statins on the endothelium could affect the relationship
Table 3 – Multivariate analysis of the association of
different cardiovascular risk factors with an abnormal
UACR.
Variable OR (95% CI) p
Age 1.03 (1.01–1.05) 0.01
Obesity 1.30 (0.86–1.97) NS
Hypertension 3.28 (2.12–5.04) <0.01
Diabetes mellitus 3.40 (2.17–5.32) <0.01
Dyslipidaemia 2.22 (1.44–3.43) <0.01
Pathological eGFR 2.87 (1.52–5.41) <0.01
NLR (per unit) 1.45 (1.20–1.74) <0.01
eGFR, estimated glomerular ﬁltration rate; NLR,
neutrophil–lymphocyte ratio; OR, odds ratio.between the NLR and an abnormal UACR.23,24 In our series,
the 196 patients being treated with statins had lower NLR val-
ues, although the difference was not statistically signiﬁcant,
(1.89 ± 0.85 for the group with statins vs 2.01 ± 0.83 for the
group without statins, p > 0.05). However, statistically signif-
icant differences were observed between the NLR of patients
with a HOMA-IR > 2, as compared to patients without insulin
resistance (1.94 ± 0.78 vs 2.05 ± 0.89 p < 0.05).
Next, the distribution of the NLR in our sample was ana-
lysed. To do this, the population was divided into 2 groups
depending on whether or not they had an abnormal UACR.
Then, patients in both subgroups were divided into 11 NLR
strata, each spanning 0.5 units, from an NLR of 0–0.5 to an NLR
of >5. As shown in Fig. 1, 87.1% of the population had NLR lev-
els between 1 and 3. Moreover, starting from an NLR value >2.5,
the relative proportion of patients with an abnormal UACR
clearly increased.
After these results were obtained, the NLR cut-off point
with the greatest abnormal UACR discriminatory capacity
was  estimated by using a sensitivity analysis. To do this, the
sensitivity, speciﬁcity, positive predictive values and negative
predictive values were calculated for NLR values between 1.5
and 3. The results can be seen in Table 4. The table shows
that the lowest NLR values had greater sensitivity for detecting
abnormal UACRs, while higher NLR values had greater speci-
ﬁcity. The results of this analysis deﬁned the values of 1.5 and
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Fig. 1 – Distribution of abnormal UACR according to NLR
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Table 4 – Analysis of sensitivity of the NLR in the
prediction of an abnormal UACR.
NLR > 1.5 NLR > 2 NLR > 2.5 NLR > 3
Sensitivity 0.80 0.5 0.3 0.18
Speciﬁcity 0.29 0.6 0.82 0.91
PPV 0.08 0.09 0.12 0.14
NPV 0.95 0.94 0.93 0.93
NLR, neutrophil–lymphocyte ratio; NPV, negative predictive value;
PPV, positive predictive value.
Low risk NLR
< 1.5
0
2
4
6
8
10
12
14
16
Medium risk
NLR 1.5-3
High risk
NLR > 3
Ab
no
rm
al
 U
AC
R 
%
p trend < 0.01
Fig. 2 – Distribution of abnormal UACR in different NLR
groups. UACR, urinary albumin/creatinine ratio; NLR,
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Table 5 – Multivariate analysis of vascular risk factors
and different cut-off points of the NLR in relation to an
abnormal UACR.
Variable OR (95% CI) p
Age 1.03 (1.01–1.05) 0.01
Obesity 1.29 (0.85–1.95) NS
Hypertension 3.32 (2.16–5.11) <0.01
Diabetes mellitus 3.51 (2.25–5.49) <0.01
Dyslipidaemia 2.18 (1.42–3.35) <0.01
Pathological eGFR 2.86 (1.51–5.41) <0.01
Neutrophil–lymphocyte ratio
NLR 1.5–3 Comparator 0.01
NLR 1.5–3 1.68 (1.03–2.76) 0.03
NLR > 3 3.14 (1.63–6.04) 0.01eutrophil–lymphocyte ratio.
 as cut-off points for the risk subgroups, given the greater
ensitivity of the former and the greater speciﬁcity of the lat-
er. The population was divided into 3 groups of patients at
isk of an abnormal UACR depending on the NLR: low risk
NLR < 1.5), intermediate risk (NLR between 1.5 and 3) and high
isk (NLR > 3). Fig. 2 shows the distribution of abnormal UACRs
n the 3 groups. It should be noted that the relative proportion
f abnormal UACRs progressively and signiﬁcantly increased
s NLR values increased.
Finally, the cut-off points for the risk subgroups were
ncluded in a multivariate model that is shown in Table 5.
atients with an NLR between 1.5 and 3 had an OR of 1.68 as
ompared to those with an NLR < 1.5. Patients with an NLR > 3
ad an increased risk up to an OR of 3.14 in the same compar-
son. This new model, which had a signiﬁcant discrimination
mprovement rate (p < 0.01), with a reclassiﬁcation improve-
ent rate of 4.05%, was subsequently analysed. This result
ould implicate the reclassiﬁcation of 74 patients in the sam-
le.
iscussion
nﬂammation plays a fundamental role in the pathophysio-
ogy of CVDs.6 Among the various markers of inﬂammation,
he NLR has been previously assessed as a predictor of mor-
ality in patients with acute coronary syndrome,25 congestive
eart failure26 and diabetes mellitus27 and patients having
ndergone a coronary catheterisation.28 In addition, it haseGFR, estimated glomerular ﬁltration rate; NLR,
neutrophil–lymphocyte ratio; OR, odds ratio.
recently been evaluated as a risk factor in a study of asymp-
tomatic patients in the cohort from Framingham’s study,
which conﬁrmed to be a powerful predictor of cardiovascu-
lar mortality. This study refers NLR as a parameter with a
potential cardiovascular risk reclassiﬁcation capacity that is
greater than other markers such as ultrasensitive CRP, the N-
terminal fragment of the B-type natriuretic peptide, glycated
haemoglobin, cystatin and homocysteine.29
Previous publications have reported an association
between NLR values and urinary albumin excretion, in both
diabetic patients30 and patients with symptomatic chronic
kidney disease.31 The importance of detecting the mecha-
nisms of endothelial damage to prevent CVD justiﬁes the use
of an abnormal UACR as an early marker of both cardiovas-
cular risk and systemic endothelial dysfunction.5,32–35 In this
study’s cohort, a clinically asymptomatic patient population,
the NLR was also signiﬁcantly correlated with an abnormal
UACR. This association was present regardless of other risk
factors associated with an abnormal UACR.
Several studies have associated inﬂammation with greater
insulin resistance.36 Recently, Lou et al.19 presented a sig-
niﬁcant correlation between an increase in the NLR and the
HOMA-IR (OR: 7.23 p < 0.01). The association between insulin
resistance and the NLR was conﬁrmed in our sample. The anti-
inﬂammatory effect of HMG-CoA reductase inhibitors could
also have an inﬂuence on the NLR.23,24 However, an article
by Gungoren et al.37 demonstrated no statistically signiﬁcant
differences in NLR among patients treated with statins and
patients not treated with statins. In our analysis, patients on
statins had a low NLR without statistical differences between
the groups. Our results may justify the study of this asso-
ciation in cohorts with a larger number of patients. Finally,
our results showed that as compared with CRP, the NLR has a
greater capacity to detect an abnormal UACR. In fact CRP did
no show statistically signiﬁcance in this context.
A useful risk marker requires to know what are the lev-
els with clinically signiﬁcance These levels can be properly
selected using a sensitivity and speciﬁcity analysis of different
cut-off points of the marker in question. This methodology has
been extensively studied and used in selecting cut-off points
in other clinical situations.22 Noteworthy in our study was the
limited sensitivity that all the levels offered, except the cut-off
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point of 1.5, which had a sensitivity of 0.80. Sensitivity is the
result of the ratio between the true positives in a test and the
sick patients in the population. A low sensitivity is related to
an increase in the false negatives in the test. As the classic
risk factors for an abnormal UACR were not found to be asso-
ciated with the NLR in our sample, many  patients would have
been false negatives if had only the NLR had been considered.
However, statistically signiﬁcant differences between the NLR
groups in the multivariate analysis validated the usefulness
of the cut-off points selected using this method.
The main limitation of our study was its cross-sectional
design, which prevented the establishment of a causal rela-
tionship between the NLR and an abnormal UACR. Moreover,
although the population recruited from a single centre limited
extrapolation of the results, the sample size and the fact that
the patients were from different regions of Spain increased the
study’s external validity. In any case, the association between
the NLR and an abnormal UACR deserves to be studied in
greater depth to determine its role not only as an inexpen-
sive, quick and non-invasive marker of cardiovascular risk but
also as a potential therapeutic target.
This study demonstrated a signiﬁcant correlation between,
clinically signiﬁcant NLR values and cardiovascular risk and
systemic endothelial dysfunction associated to microvascu-
lar disease in a cohort of asymptomatic patients. Given the
limitations set forth above, interventional, multi-centre stud-
ies with a greater number of outcomes are required to assess
other potential clinical implications of this ﬁnding.
Conclusion
The NLR may represent a new tool for the assessment
of cardiovascular risk and the risk of systemic endothelial
dysfunction associated with microvascular disease in asymp-
tomatic patients.
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Appendix  A.  Supplementary  data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.nefroe.2016.11.003.
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